^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMP7068

    i
    Other names: IMP7068, IMP-7068, IMP 7068
    Associations

    News

    Trials
    Company:
    IMPACT Therap
    Drug class:
    WEE1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    Targeting WEE1 Kinase for Breast Cancer Therapeutics: An Update. (PubMed, Int J Mol Sci)
    Adavosertib's clinical promise was challenged by inter-individual variations in response and side effects. Because of these promising preclinical outcomes, other WEE1 kinase inhibitors (Azenosertib, SC0191, IMP7068, PD0407824, PD0166285, WEE1-IN-5, Zedoresertib, WEE1-IN-8, and ATRN-1051) are being developed, with several currently being evaluated in clinical trials or as an adjuvant to chemotherapies...Reliable predictors of clinical responses based on mechanistic insights remain an important unmet need. Herein, we review the role of WEE1 inhibition therapy in breast cancer.
    Review • Journal
    |
    STING (stimulator of interferon response cGAMP interactor 1) • CDK2 (Cyclin-dependent kinase 2) • CDC25C (Cell Division Cycle 25C) • CDK1 (Cyclin-dependent kinase 1) • PKMYT1 (Protein Kinase Membrane Associated Tyrosine/Threonine 1) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
    |
    adavosertib (AZD1775) • azenosertib (ZN-c3) • SC0191 • APR-1051 • IMP7068
    over2years
    Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors (ESMO 2023)
    80mg was defined as a potential PR2D in 3/4 schedule, and a second potential RP2D is being explored in 5/2 schedule. RP2D for IMP7068 will be determined soon.
    Clinical • Metastases
    |
    CDK1 (Cyclin-dependent kinase 1)
    |
    IMP7068
    3years
    WEE1: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=350, Recruiting, Impact Therapeutics, Inc. | N=150 --> 350
    Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MSI-H/dMMR • NTRK fusion
    |
    IMP7068
    over4years
    WEE1: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, Impact Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MSI-H/dMMR • NTRK fusion
    |
    IMP7068
    almost5years
    WEE1: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=150, Not yet recruiting, Impact Therapeutics, Inc.
    Clinical • New P1 trial
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MSI-H/dMMR • NTRK fusion
    |
    IMP7068